The prevalence of onychomycosis in the global population – A literature study

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue 11, 2014, Pages 1480-1491

  Sigurgeirsson, B ^a   Baran, R ^b  

^a UNIVERSITY OF ICELAND   (Iceland)

^b NAIL DISEASE CENTRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DERMATOPHYTE; EUROPE; HOSPITAL; HUMAN; INFORMATION RETRIEVAL; MEDLINE; MOULD; NORTH AMERICA; ONYCHOMYCOSIS; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SEX RATIO; SYSTEMATIC REVIEW; TOENAIL ONYCHOMYCOSIS; TRICHOPHYTON RUBRUM; YEAST;

EID: 85006371251     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12323     Document Type: Article

References (67)

1. Sigurgeirsson B, Olafsson JH, Steinsson JB, Paul C, Billstein S, Evans EG. Long-term effectiveness of treatment with terbinafine vs. itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 2002; 138: 353–357.
2. Shuster S, Baran R. Recurrence of fungal nail disease and the dissociation of relapse from re-infection. Acta Derm Venereol 2001; 81: 154–155.
3. Scher RK, Tavakkol A, Sigurgeirsson B et al. Onychomycosis: diagnosis and definition of cure. J Am Acad Dermatol 2007; 56: 939–944.
4. Faergemann J, Baran R. Epidemiology, clinical presentation and diagnosis of onychomycosis. Br J Dermatol 2003; 149 (Suppl 65): 1–4.
5. Gupta AK, Jain HC, Lynde CW, Macdonald P, Cooper EA, Summerbell RC. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15 000 patients. J Am Acad Dermatol 2000; 43: 244–248.
6. Ghannoum M, Isham N, Henry W, Kroon HA, Yurdakul S. Evaluation of the morphological effects of TDT 067 (terbinafine in transfersome) and conventional terbinafine on dermatophyte hyphae in vitro and in vivo. Antimicrob Agents Chemother 2012; 56: 2530–2534.
7. Moriarty B, Hay R, Morris-Jones R. The diagnosis and management of tinea. BMJ 2012; 345: e4380.
8. Elewski B, Pollak R, Ashton S, Rich P, Schlessinger J, Tavakkol A. A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol 2012; 166: 389–398.
9. Zhang RN, Wang DK, Zhuo FL, Duan XH, Zhang XY, Zhao JY. Long-pulse Nd:YAG 1064 nm laser treatment for onychomycosis. Chin Med J (Engl) 2012; 125: 3288–3291.
10. Luk NM, Hui M, Cheng TS, Tang LS, Ho KM. Evaluation of PCR for the diagnosis of dermatophytes in nail specimens from patients with suspected onychomycosis. Clin Exp Dermatol 2012; 37: 230–234.
11. Gupta AK, Simpson FC. Medical devices for the treatment of onychomycosis. Dermatol Ther 2012; 25: 574–581.
12. Shemer A. Update: medical treatment of onychomycosis. Dermatol Ther 2012; 25: 582–593.
13. ®): a carrier-based dosage form of terbinafine for onychomycosis. Expert Opin Investig Drugs 2012; 21: 1549–1562.
14. Gupta AK, Simpson FC. New therapeutic options for onychomycosis. Expert Opin Pharmacother 2012; 13: 1131–1142.
15. Nenoff P, Ginter-Hanselmayer G, Tietz HJ. Fungal nail infections–an update: part 1–Prevalence, epidemiology, predisposing conditions, and differential diagnosis. Hautarzt 2012; 63: 30–38.
16. Grover C, Khurana A. Onychomycosis: newer insights in pathogenesis and diagnosis. Indian J Dermatol Venereol Leprol 2012; 78: 263–270.
17. Ozkan F, Ozturk P, Ozyurt K et al. Frequency of peripheral arterial disease and venous insufficiency in toenail onychomycosis. J Dermatol 2012; 40: 107–110.
18. Hees H, Raulin C, Bäumler W. Laser treatment of onychomycosis: an in vitro pilot study. J Dtsch Dermatol Ges 2012; 10: 913–918.
19. Gupta AK, Paquet M, Simpson F, Tavakkol A. Terbinafine in the treatment of dermatophyte toenail onychomycosis: a meta-analysis of efficacy for continuous and intermittent regimens. J Eur Acad Dermatol Venereol 2012; 27: 267–272.
20. Halim I, El Kadioui F, Soussi Abdallaoui M. Onychomycosis in Casablanca (Morocco). J Mycol Med 2012 doi: 10.1016/j.mycmed.2012.10.002 [Epub ahead of print].
21. Tchernev G, Penev PK, Nenoff P et al. Onychomycosis: modern diagnostic and treatment approaches. Wien Med Wochenschr 2012 doi: 10.1007/s10354-012-0139-3 [Epub ahead of print].
22. Gupta A, Simpson F. Device-based therapies for onychomycosis treatment. Skin Therapy Lett 2012; 17: 4–9.
23. Relloso S, Arechavala A, Guelfand L et al. Onychomycosis: multicentre epidemiological, clinical and mycological study. Rev Iberoam Micol 2012; 29: 157–163.
24. Nazar JR, Gerosa PE, Díaz OA. Onychomycoses: epidemiology, causative agents and assessment of diagnostic laboratory methods. Rev Argent Microbiol 2012; 44: 21–25.
25. Grover C, Khurana A. An update on treatment of onychomycosis. Mycoses 2012; 55: 541–551.
26. Emtestam L, Kaaman T, Rensfeldt K. Treatment of distal subungual onychomycosis with a topical preparation of urea, propylene glycol and lactic acid: results of a 24-week, double-blind, placebo-controlled study. Mycoses 2012; 55: 532–540.
27. Zisova L, Valtchev V, Sotiriou E, Gospodinov D, Mateev G. Onychomycosis in patients with psoriasis–a multicentre study. Mycoses 2012; 55: 143–147.
28. Herpay Z, Pintye I, Halmy K. Zur Pilzflora in einem Landdorf im Bezirk Debrecen. Mycoses 1969; 12: 369–374.
29. Rea JN, Newhouse ML, Halil T. Skin disease in Lambeth. A community study of prevalence and use of medical care. Br J Prev Soc Med 1976; 30: 107–114.
30. Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol 1992; 126(Suppl 39): 23–27.
31. Sais G, Jucglà A, Peyrí J. Prevalence of dermatophyte onychomycosis in Spain: a cross-sectional study. Br J Dermatol 1995; 132: 758–761.
32. Anonymous. Prevalence, morbidity, and cost of dermatological diseases. J Invest Dermatol 1979;73:395–401.
33. Heikkilä H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol 1995; 133: 699–703.
34. Sigurgeirsson B, Steingrímsson O, Sveinsdóttir S. Prevalence of onychomycosis in Iceland: a population-based study. Acta Derm Venereol 2002; 82: 467–469.
35. Pönnighaus JM, Clayton Y, Warndorff D. The spectrum of dermatophytes in northern Malawi (Africa). Mycoses 1996; 39: 293–297.
36. Vanbreuseghem R. Prevalence of onychomycoses in Zaire, especially in sugar cane cutters. Ann Soc Belg Med Trop 1977; 57: 7–15.
37. Arenas R, Bonifaz A, Padilla MC et al. Onychomycosis. A Mexican survey. Eur J Dermatol 2010; 20: 611–614.
38. Gupta AK, Lynde CW, Jain HC et al. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. Br J Dermatol 1997; 136: 786–789.
39. Holme SA, Scott-Lang VE, Ooi ET et al. The South-East Scotland dermatology workload study: 30 years' analysis. Br J Dermatol 2012; 167: 123–130.
40. Benton EC, Kerr OA, Fisher A, Fraser SJ, McCormack SK, Tidman MJ. The changing face of dermatological practice: 25 years' experience. Br J Dermatol 2008; 159: 413–418.
41. Gupta AK, Jain HC, Lynde CW, Watteel GN, Summerbell RC. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada–a multicenter survey of 2001 patients. Int J Dermatol 1997; 36: 783–787.
42. Perea S, Ramos MJ, Garau M, Gonzalez A, Noriega AR, del Palacio A. Prevalence and risk factors of tinea unguium and tinea pedis in the general population in Spain. J Clin Microbiol 2000; 38: 3226–3230.
43. Seebacher C. Fungal flora of diseased and healthy toenails. Mykosen 1968; 11: 893–902.
44. Summerbell RC, Cooper E, Bunn U, Jamieson F, Gupta AK. Onychomycosis: a critical study of techniques and criteria for confirming the etiologic significance of nondermatophytes. Med Mycol 2005; 43: 39–59.
45. Sabouraud RJA. Les Teignes. Masson, Paris, 1910.
46. Drakensjö IT, Chryssanthou E. Epidemiology of dermatophyte infections in Stockholm, Sweden: a retrospective study from 2005 to 2009. Med Mycol 2011; 49: 484–488.
47. Sahin I, Oksuz S, Kaya D, Sencan I, Cetinkaya R. Dermatophytes in the rural area of Duzce Turkey. Mycoses 2004; 47: 470–474.
48. del Palacio A, Cuétara MS, Garau M, Perea S. Onychomycosis: a prospective survey of prevalence and etiology in Madrid. Int J Dermatol 2006; 45: 874–876.
49. Walshe MM, English MP. Fungi in nails. Br J Dermatol 1966; 78: 198–207.
50. Vélez A, Linares MJ, Fenández-Roldán JC, Casal M. Study of onychomycosis in Córdoba, Spain: prevailing fungi and pattern of infection. Mycopathologia 1997; 137: 1–8.
51. Elewski BE, Charif MA. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol 1997; 133: 1172–1173.
52. Abeck D, Haneke E, Nolting S, Reinel D, Seebacher CO. Aktuelle Daten zu Epidemiologie, Erregerspektrum, Risikofaktoren sowie Beeinflussung der Lebensqualität. Dt Ärztebl 2000; 97: 1984–1986.
53. Ghannoum MA, Hajjeh RA, Scher R et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 2000; 43: 641–648.
54. Cheng S, Chong L. A prospective epidemiological study on tinea pedis and onychomycosis in Hong Kong. Chin Med J (Engl) 2002; 115: 860–865.
55. Chan MK, Chong LY. Achilles Project Working Group in Hong Kong. A prospective epidemiologic survey on the prevalence of foot disease in Hong Kong. J Am Podiatr Med Assoc 2002; 92: 450–456.
56. Sergeev AY, Ivanov OL, Sergeev YV et al. Epidemiology of onychomycosis in modern Russia: Incidence is growing. Mycoses 2002;45:56.
57. Araújo AJG, Bastos OMP, Souza MAJ, Oliveira JC. Occurrence of onychomycosis among patients attended in dermatology offices in the city of Rio de Janeiro Brazil. An Bras Dermatol 2003; 78: 299–308.
58. Burzykowski T, Molenberghs G, Abeck D et al. High prevalence of foot diseases in Europe: results of the Achilles Project. Mycoses 2003; 46: 496–505.
59. Roseeuw D. Achilles foot screening project: preliminary results of patients screened by dermatologists. J Eur Acad Dermatol Venereol 1999;12 Suppl 1:S6–S9; discussion S17.
60. Haneke E, Roseeuw D. The scope of onychomycosis: epidemiology and clinical features. Int J Dermatol 1999; 38(Suppl 2): 7–12.
61. Svejgaard EL, Nilsson J. Onychomycosis in Denmark: prevalence of fungal nail infection in general practice. Mycoses 2004; 47: 131–135.
62. Ungpakorn R, Lohaprathan S, Reangchainam S. Prevalence of foot diseases in outpatients attending the Institute of Dermatology, Bangkok, Thailand. Clin Exp Dermatol 2004; 29: 87–90.
63. Djeridane A, Djeridane Y, Ammar-Khodja A. Epidemiological and aetiological study on tinea pedis and onychomycosis in Algeria. Mycoses 2006; 49: 190–196.
64. Ioannidou DJ, Maraki S, Krasagakis SK, Tosca A, Tselentis Y. The epidemiology of onychomycoses in Crete, Greece, between 1992 and 2001. J Eur Acad Dermatol Venereol 2006; 20: 170–174.
65. Watanabe S, Harada T, Hiruma M et al. Epidemiological survey of foot diseases in Japan: results of 30 000 foot checks by dermatologists. J Dermatol 2010; 37: 397–406.
66. Nkondjo Minkoumou S, Fabrizi V, Papini M. Onychomycosis in Cameroon: a clinical and epidemiological study among dermatological patients. Int J Dermatol 2012;51:1474–1477.
67. Chiacchio ND, Suarez MV, Madeira CL, Loureiro WR. An observational and descriptive study of the epidemiology of and therapeutic approach to onychomycosis in dermatology offices in Brazil. An Bras Dermatol 2013; 88 (Suppl 1): 3–11.